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A B S T R A C T  
Background: Hepatitis C virus (HCV) is a major cause of chronic liver disease (CLD). Pakistan has a high burden of infectious 
diseases, including HCV. Its prevalence varies according to geographic regions in the country from about 2·4% to 6·5%. The 
objective of the study was to compare the frequency of vitamin D deficiency in responders and non-responders of antiviral treatment 
for chronic hepatitis C. 
Material and Methods: This comparative cross-sectional study was conducted in Hepatitis Clinic, Jinnah hospital, Lahore from 
20th May to 20th November 2013. After ethical approval, participants were selected by using purposive non-probability sampling, 52 
responder patients i.e. who were labeled negative for HCV RNA by PCR after 12 weeks of antiviral treatment and 52 non-responder 
patients were included in this study. Data was collected by using pretested structured questionnaire. Vitamin D3 levels were 
measured by ELISA and a cut-off value of below 30ng/ml was labeled as Vitamin D deficiency. SPSS version 21 was used to 
analyze data with p value less than 0.05 taken as statistically significant. 
Results: Out of 104 patients (mean age 35±8.1 years), 61.5% were males and 38.5 % were females. There was a significant 
difference in frequency of vitamin D deficiency in treatment responder group when compared to non-responders (p = 0.016).  Mean 
level of vitamin D was 21.8±10.8ng/ml in responders whereas it was 15.6±7.5 in non-responders with a statistically significant 
difference (p = 0.001). 
Conclusion: This study concludes that there is a significant vitamin D deficiency among treatment non-responders as compared to 
treatment responders in patients with chronic hepatitis C. 
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I n t r o d u c t i o n  
 
Hepatitis C virus (HCV) is a major cause of chronic liver 
disease (CLD). It is a global dilemma and an alarming 
health issue with global incidence of 200 million (3.3%).1 
Pakistan also has a high burden of infectious disease 
including HCV2,3. Its prevalence varies according to 
geographic regions from about 2·4% to 6·5%.4,5 However, 
very low rate of HCV is reported from developed nations 
like Canada 0.8%, France 1.1%, Germany 0.6%, and 
Australia 1.1%. Similarly, prevalence rate of HCV lower 
than Pakistan have also been reported from Italy (2.2%) 
USA (1.8%), Japan (12.3%) and China (3.2%) 
respectively.6-10 Whereas, Africa and Asia have the 
highest burden of HCV infection. Egypt alone with an 
estimated population of almost 73 million11 has a high 
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seroprevalence rate of about 22%.12 Liver is a vital organ 
for the metabolism of Vitamin D. It hydrolyzes vitamin D 
from skin and diet into 25-hydroxyvitamin D [25(OH)D] 
which can be estimated by ELISA13. Therefore, liver 
disease affect the metabolism of Vitamin D leading to 
disturbance in calcium and bone metabolism.14 Deficiency 
of vitamin D is associated with osteopenia, osteoporosis, 
osteomalacia and muscle weakness, resulting in  higher 
chances of bone fractures.15 Moreover, Vitamin D 
deficiency is associated with multiple types of 
malignancies (e.g., prostate, colon, breast), as well as 
autoimmune inflammatory metabolic disorders. Vitamin D 
also plays a major role in calcium metabolism and in 
differentiation, proliferation and immunomodulation of 
cells.16 Similarly, Vitamin D deficiency resists fibroblastic 
proliferation and augments the production of collagen. 
HCV infection leads to Chronic Liver Disease (CLD)17 and 
eventually to hepatic fibrosis.18 It is therefore essential to 
understand the role of vitamin D deficiency in the 
treatment of chronic hepatitis C, so that these patients 
may be screened and treated before starting the antiviral 
therapy. 
 
M a t e r i a l  a n d  M e t h o d s  
This comparative cross-sectional study was `conducted in 
Hepatitis Clinic, Jinnah hospital, Lahore from 20th May to 
20th November, 2013 after obtaining approval from the 
institutional ethics committee. Non-probability purposive 
sampling technique was used for sample collection. 
Patients of either sex of age 20-60 years, coming for 
follow up in hepatitis clinic of Jinnah Hospital Lahore were 
enrolled in this study. All patients had received 12-week 
treatment for chronic hepatitis C i.e. conventional 
interferon injection and ribavirin tablets. Patient taking 
calcium/ Vitamin D supplementation, having advanced 
impaired liver and /or renal functions were excluded from 
the study.  
 
After informed consent, 52 responders and 52 non-
responder patients were segregated into 2 groups.  Data 
was collected using pretested structured questionnaire. 
Blood samples were collected using aseptic technique 
and vitamin D3 levels were assessed by Enzyme-Linked 
Immunosorbent Assay (ELISA). Genotype of HCV was 
also recorded to cater for effect modification. Data was 
entered and analyzed in SPSS version 21. Frequencies 
and percentages were calculated for qualitative variables 
while mean and standard deviation were computed for 
quantitative variables. Vitamin D deficiency was 
compared in both groups i.e. responders and non-
responders using chi square test of homogeneity as a test 
of significance, with p value less than or equal to 0.05. 
Data was cross tabulated to determine the effect of age, 
sex and genotyping on treatment response and Vitamin D 
deficiency. Independent sample t test and Chi square 
were used to rule out effect of these confounders. Vitamin 
D deficient patients were divided into two classes i.e. 
severe deficiency, if Vit D level less was than 15 ng/ml 
and deficiency, if levels were between 15 and 30ng/ml. 
The difference in responders and non-responders was 
cross tabulated again. 
 
R e s u l t s  
Out of 104 patients i.e. 52 responders and 52 non-
responders, patients with mean age of 35.3  8.1 years 
were included. Mean vitamin D level came out to be 18.8 
ng/ml  9.7 (range 7.7 to 44 ng/ml). There were 61.5% 
(n=64) males and 38.4% (n=40) females, respectively. 
Genotype distribution showed 79 patients (76%) with 
genotype 3, 19 Patients (18%) had type 1 and only 6 
patients (5.8%) had type 2 genotype of hepatitis C virus. 
Out of 104 patients 82 individuals (79%) were vitamin D 
deficient. Mean level of vitamin D was 21.8  10.8 ng/ml 
in responders while it was 15.6 7.5 ng/ml in non-
responders. Cross tabulation of vitamin D deficiency 
categories and treatment response groups among 
Hepatitis C patients, showed significant difference of 
Vitamin D Deficiency among treatment responders as 
compared to non-responders (p= 0.016) (Table I). 
Response to antiviral treatment is also significantly 
associated with genotype of Hepatitis C (p = 0.05). To 
rule out the effect of age and gender, we cross tabulated 
age groups of patients in both groups i.e. > 30 years and 
<30 years and gender with treatment response, which 
showed that younger patients have a better response to 
treatment than older groups. There was no correlation of 
gender with treatment response (p=0.314) (Table II).  
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Table III: Vitamin D levels in HCV treatment Responders and Non-Responders and different HCV genotypes 
 
Variables 
Groups   
Total 
 
P Value Severely deficient Deficient Normal 
Study groups 
Responders 22 14 16 52 
Pearson Chi square 0.026 
Non-responders 34 12 6 52 
HCV genotype 
Gen 3 43 21 15 79 
Fisher’s Exact <0.865 Gen 2 3 1 2 6 
Gen 1a or 1b 10 4 5 19 
Table IV: Distribution of Vitamin D levels according to Gender and Age groups 
 
Variables 
Groups   
Total 
 
P Value Severely deficient Deficient Normal 
Gender 
Male 34 19 11 64 
Pearson Chi square 0.257 
Female 22 7 11 40 
Age Grous 
>30 years 43 18 9 70 
Pearson Chi square 0.01 
< 30 years 13 8 13 34 
 
An inverse relationship of response to interferon therapy 
with Vitamin D deficiency was also reported (p=0.026). 
Severity of vitamin D deficiency is not related to genotype 
and gender but is affected by age (Tables III and IV). 
 
D i s c u s s i o n  
The mean age of patients in our study shows that 
hepatitis has affected our population in the most 
productive age group. Similarly, vitamin D deficiency is 
also very common involving almost 80% of our 
population. Genotype 3 is the main circulating viral 
genotype in our population, and is easily treatable. Our 
results also show higher frequency of Genotype 3 in  
 
treatment responders. Although previous studies showed 
that vitamin D levels are not associated with sustained 
virologic response (SVR) to antiviral therapy (PEG-IFN 
and RBV) in hepatitis C patients, but effect of Vitamin D 
supplementation on SVR was not clear.19 However, our 
study showed that Vitamin D deficiency has significant 
negative correlation with response to hepatitis C 
treatment; but the causal relationship cannot be elicited 
due to the limitation of the study design. Kitson et al 
reported mean 25(OH)D level of 79.6 nmol/L, with 48% 
prevalence of 25(OH)D <75 nmol/L and 16% <50 nmol/L 
respectively in Chronic Hepatitis C genotype 1 patients. 
Their study showed no association of baseline 25(OH) 
level with SVR or fibrosis in HCV-1, but significant 
association with high activity grade.20 Similarly, Ladero et 
Table I: Cross tabulation of Vit D deficiency and HCV genotypes with responder and non-responders 
 Groups   
Responders Non-Responders Total P Value 
Vitamin D level Normal 16 6 22 Pearson Chi square 0.016 
Deficient 36 46 82 
Genotypes Gen 3 45 34 79 Fisher’s Exact 0.05 
Gen 2 2 4 6 
Gen 1a or 1b 5 14 19 
Table II: Cross tabulation of Vit D deficiency and HCV genotypes with responder and non-responders 
 Groups   
Responders Non-Responders Total P Value 
Gender  Male 29 35 64 Pearson Chi square 0.314 
Female 23 17 40 
Age group >30 years 22 48 70 Fisher’s Exact <0.001 
<30 years 30 4 34 
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al also mentioned presence of vitamin D deficiency 
among Spanish chronic hepatitis C patients.21 About 41 
vitamin D deficient patients were treated with vitamin D 
supplements and later on re-evaluated. Vitamin D 
deficiency (<20ug/dl) was seen in 36.1% and suboptimal 
levels (20-30ug/dl) were observed in 40.9% patients.21 
Our study findings are in agreement with Mohamed et al22 
who reported low vitamin D levels in HCV patients as 
compared to the healthy population. Higher levels of 
Vitamin D were observed among responders of ribavirin 
plus Pegylated interferon alpha 2a therapy while low 
levels were observed among non-responders. Therefore, 
it was concluded that vitamin D deficiency may contribute 
to delayed or unfavorable response of antiviral therapy in 
HCV infected patients.  
 
Another study by Amanzada et al showed that lower pre-
treatment 25(OH)D levels and higher serum ferritin levels 
were significantly associated with fibrotic alteration and 
inflammatory activity.23 Yu et al also reported significantly 
lower concentration of 25(OH)D in liver cirrhosis group 
than the control group with the conclusion that vitamin D 
might function as a protective factor against development 
of cirrhosis.24 
Similarly, Villar et al reported in a systematic review that 
out of 1575 Hepatitis C patients, 1117 (71%) were vitamin 
D deficient. With respect to treatment, this systemic 
review had included 8 studies of both HCV persons 
without previous treatment and pooled patients with 
sustained viral response. In patients with very high SVR, 
Vitamin D levels was >30 ng/dl which could be either 
supplemented or natural regardless of types of genotype. 
The results established high occurrence of vitamin D 
deficiency in Hepatitis C patients and SVR in persons with 
upper vitamin D levels or in patients getting vitamin D 
supplementation.25 
 
C o n c l u s i o n  
There is a significant difference in vitamin D levels among 
treatment responders and non-responders in patients with 
chronic Hepatitis C, with a very low rate of vitamin D 
observed among non-responders. Severity of vitamin D 
deficiency is not related to genotype and gender but is 
affected by age. It is hereby recommended to screen 
every patient before the start of antiviral treatment for a 
better outcome of Hepatitis treatment. 
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